--- title: "Citius Oncology (CTOR) news: going concern and offering" url: "https://aibio.space/companies/citius-oncology/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CTOR going concern, offering and Nasdaq notice news: Citius Oncology gets Nasdaq minimum bid price deficiency notice, has until October 19, 2026." --- CTOR Citius Oncology, Inc. NASDAQ · United States # Citius Oncology (CTOR) news CTOR going concern, offering and Nasdaq notice news Listings · 2026-10-23 ## [Citius Oncology gets Nasdaq extension to April 19, 2027 on bid price](https://aibio.space/news/citius-oncology-gets-nasdaq-extension-april-19-2027-bid-price/) Citius Oncology has until April 19, 2027 to show a closing bid of $1.00 or more for ten consecutive business days. Its parent owned about 77.9% of the company in December 2025, and fiscal 2025 cash used in operations was $5.5 million against a net loss of $24.8 million. ## Latest Citius Oncology news 1. 2026-08-21 Listings [Citius Pharmaceuticals gets Nasdaq extension to February 8, 2027 on bid price](https://aibio.space/news/citius-pharmaceuticals-gets-nasdaq-extension-february-8-2027-bid-price/) Nasdaq gave Citius Pharmaceuticals until February 8, 2027 to show compliance with its $1.00 minimum bid price. The 8-K gives no closing price and no plan, and the company says it cannot assure it will regain compliance. 2. 2026-05-06 Debt Financing [Citius Oncology prices $11.5 million warrant inducement and signs Avenue term loan](https://aibio.space/news/citius-oncology-prices-11-5-million-warrant-inducement-signs-avenue/) Citius Oncology signed a warrant inducement worth about $11.5 million and a loan of up to $25.0 million with Avenue. Existing warrants are repriced to $0.90, and the new warrants and conversion rights add to the share count. 3. 2026-05-06 Debt Financing [Citius Oncology announces up to $36.5 million in loan and warrant financing](https://aibio.space/news/citius-oncology-announces-up-36-5-million-loan-warrant-financing/) Citius Oncology signed a loan of up to $25 million with an Avenue Capital fund and expects about $11.5 million gross from a warrant exercise. Only $10 million of the loan funds at closing, and the new warrants cannot be exercised until stockholders approve the shares. 4. 2026-04-28 Listings [Citius Oncology gets Nasdaq minimum bid price deficiency notice, has until October 19, 2026](https://aibio.space/news/citius-oncology-gets-nasdaq-minimum-bid-price-deficiency-notice-has/) Nasdaq says the stock closed below $1.00 for 30 consecutive business days. The company has until October 19, 2026 to cure, while its auditor has flagged going-concern doubt and its parent funds most operations. 5. 2026-04-24 Financings [Citius Pharmaceuticals prices $5 million registered direct offering at $0.985](https://aibio.space/news/citius-pharmaceuticals-prices-5-million-registered-direct-offering-0/) Citius Pharmaceuticals sold 4,730,457 shares at $0.985 and pre-funded warrants for 345,686 shares, and it will issue warrants at $0.86 a share. The prospectus supplement also reports substantial doubt about its ability to continue as a going concern. 6. 2025-05-14 Distress [Citius Oncology 10-Q cites auditor's going-concern doubt](https://aibio.space/news/citius-oncology-10-q-cites-auditors-going-concern-doubt/) Citius Oncology reported $112 in cash at March 31, 2025 and negative working capital of about $31.7 million. Its parent had sufficient capital to fund it only through May 2025, and Nasdaq gave it until October 20, 2025 to fix its bid price. 7. 2025-05-14 Distress [Citius Pharmaceuticals 10-Q cites going-concern doubt and Nasdaq compliance](https://aibio.space/news/citius-pharmaceuticals-10-q-cites-going-concern-doubt-nasdaq/) The company had $26,410 in cash at March 31, 2025. Its own estimate says cash, including $1.735 million of net proceeds from an April offering, lasts only through May 2025, and it lost $21,792,751 in the six months to March 31. 8. 2025-02-14 Listings [Citius Pharmaceuticals reports $1.1 million cash and expects to raise capital](https://aibio.space/news/citius-pharmaceuticals-reports-1-1-million-cash-expects-raise-capital/) Citius Pharmaceuticals ended its fiscal first quarter with $1,100,079 in cash, after operations used $4,725,852 and inventory absorbed $6,112,603. The release does not name a placement agent for the offerings it describes. 9. 2025-01-06 Distress [Citius Oncology hires Jefferies to explore strategic alternatives](https://aibio.space/news/citius-oncology-hires-jefferies-explore-strategic-alternatives/) Citius Oncology has set no timeline for its strategic review, and the release says there is no assurance it will produce a deal. Its parent owns 92% of the company and has funded it since the subsidiary was formed. ## Citius Oncology at a glance - **Ticker**: CTOR - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $16.6 million ### Related companies - [MabCure](https://aibio.space/companies/mabcure/) OTC: MBCI - [Pfizer](https://aibio.space/companies/pfizer-pfe/) NYSE: PFE - [Praxis Precision Medicines](https://aibio.space/companies/praxis-precision-medicines/) NASDAQ: PRAX - [Sutro Biopharma](https://aibio.space/companies/sutro-biopharma/) NASDAQ: STRO - [Viking Therapeutics](https://aibio.space/companies/viking-therapeutics/) NASDAQ: VKTX - [Akebia Therapeutics](https://aibio.space/companies/akebia-therapeutics/) NASDAQ: AKBA - [Dare Bioscience](https://aibio.space/companies/dare-bioscience/) NASDAQ: DARE - [Mangoceuticals](https://aibio.space/companies/mangoceuticals/) NASDAQ: MGRX ### Also on NASDAQ - [Fortrea Holdings](https://aibio.space/companies/fortrea/) FTRE - [Evogene](https://aibio.space/companies/evogene/) EVGN - [Zentalis Pharmaceuticals](https://aibio.space/companies/zentalis-pharmaceuticals/) ZNTL - [Psyence Biomedical](https://aibio.space/companies/psyence-biomedical/) PBM - [NewcelX](https://aibio.space/companies/newcelx/) NCEL - [Kazia Therapeutics](https://aibio.space/companies/kazia-therapeutics/) KZIA ## What Citius Oncology does Citius Oncology is a biopharmaceutical company headquartered in Cranford, New Jersey, that develops and commercializes targeted oncology therapies. Its strategy centers on new formulations of previously approved drugs and expanded indications for approved therapies. Its lead product is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for persistent or recurrent cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The FDA approved LYMPHIR in August 2024 and the product launched in December 2025. The company estimates the market for LYMPHIR to exceed $400 million and describes it as underserved by existing treatments. It plans to commercialize its products independently in the U.S. and to partner for sales outside the U.S., with a small sales force focused mainly on major cancer centers. The license came from Eisai Co., Ltd., and the related asset purchase from Dr. Reddy's Laboratories SA. Citius Pharma owned approximately 77.9% of the company as of December 17, 2025. | Product or program | What it is | Stage | |---|---|---| | LYMPHIR (denileukin diftitox-cdxl) | Engineered IL-2 diphtheria toxin fusion protein for persistent or recurrent cutaneous T-cell lymphoma | approved in the US in August 2024; launched in December 2025 | Summarised from the company's [10-K filed Dec 23, 2025](https://www.sec.gov/Archives/edgar/data/1851484/000121390025125331/ea0270097-10k_citius.htm). ## Citius Oncology annual financials | Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 | |---|---|---| | Research and development | [$6.4 million](https://www.sec.gov/Archives/edgar/data/1851484/000121390025125331/) | [$4.9 million](https://www.sec.gov/Archives/edgar/data/1851484/000121390025125331/) | | Net income (loss) | [-$24.8 million](https://www.sec.gov/Archives/edgar/data/1851484/000121390025125331/) | [-$21.1 million](https://www.sec.gov/Archives/edgar/data/1851484/000121390025125331/) | | Cash from operations | [-$5.5 million](https://www.sec.gov/Archives/edgar/data/1851484/000121390025125331/) | [$126,353](https://www.sec.gov/Archives/edgar/data/1851484/000121390025125331/) | | Cash and equivalents | [$3.9 million](https://www.sec.gov/Archives/edgar/data/1851484/000121390026090184/) | [$112](https://www.sec.gov/Archives/edgar/data/1851484/000121390025043359/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $16.6 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Citius Oncology Has Citius Oncology issued a going-concern warning? Our latest story on this, dated Apr 28, 2026: "Citius Oncology gets Nasdaq minimum bid price deficiency notice, has until October 19, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/citius-oncology-gets-nasdaq-minimum-bid-price-deficiency-notice-has/). Has Citius Oncology raised money recently? Our latest story on this, dated Apr 24, 2026: "Citius Pharmaceuticals prices $5 million registered direct offering at $0.985". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/citius-pharmaceuticals-prices-5-million-registered-direct-offering-0/). Has Citius Oncology received a Nasdaq deficiency notice? Our latest story on this, dated Apr 28, 2026: "Citius Oncology gets Nasdaq minimum bid price deficiency notice, has until October 19, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/citius-oncology-gets-nasdaq-minimum-bid-price-deficiency-notice-has/). What is the ticker symbol of Citius Oncology? Citius Oncology, Inc. trades under the ticker CTOR on NASDAQ. Where is Citius Oncology listed? Citius Oncology, Inc. is listed on NASDAQ. What is the SEC CIK of Citius Oncology? The SEC Central Index Key (CIK) for Citius Oncology, Inc. is 1851484. Its filings are on SEC EDGAR. How many shares does Citius Oncology have outstanding? 92,981,204 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Citius Oncology listed under? Our directory records Citius Oncology, Inc. under United States. What does Citius Oncology do? Our directory classifies Citius Oncology, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Citius Oncology? The ISIN recorded for Citius Oncology, Inc. is US17331Y1091. Does aibio.space cover Citius Oncology? aibio.space lists Citius Oncology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Citius Oncology incorporated? SEC records list its state or country of incorporation as DE. What does Citius Oncology develop? Citius Oncology is a biopharmaceutical company headquartered in Cranford, New Jersey, that develops and commercializes targeted oncology therapies. Its strategy centers on new formulations of previously approved drugs and expanded indications for approved therapies. What is LYMPHIR (denileukin diftitox-cdxl) from Citius Oncology? LYMPHIR (denileukin diftitox-cdxl): Engineered IL-2 diphtheria toxin fusion protein for persistent or recurrent cutaneous T-cell lymphoma Stage: approved in the US in August 2024; launched in December 2025. Is Citius Oncology profitable? Citius Oncology, Inc. reported a net loss of $24.8 million for the fiscal year ended Sep 30, 2025, and used $5.5 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Citius Oncology Members talk about Citius Oncology (CTOR). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Citius Oncology, newest first. Each line links the filing it comes from. 1. 2026-10-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1851484/000121390026112109/ea0309307-8k_citius.htm) 2. 2026-05-06 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1851484/000121390026052552/ea028929701ex99-1.htm) 3. 2026-04-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1851484/000121390026048629/ea0288020-8k_citius.htm) 4. 2025-12-10 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1851484/000121390025119760/ea0268966-424b5_citius.htm) 5. 2025-09-02 Financings Reported a financing. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1851484/000121390025082919/ea0254958-s3_citius.htm) 6. 2025-07-14 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1851484/000121390025063483/ea0242842-s1_citius.htm) 7. 2025-06-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1851484/000121390025059084/ea024719201-8k_citius.htm) 8. 2025-05-14 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1851484/000121390025043359/ea0241639-10q_citius.htm) 9. 2025-04-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1851484/000121390025035575/ea0239433-8k_citius.htm) 10. 2025-01-06 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1851484/000121390025000953/ea022666501ex99-1_citius.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CTOR on TradingView](https://www.tradingview.com/symbols/NASDAQ-CTOR/). ## SEC filings and registration - **SEC name**: Citius Oncology, Inc. - **CIK**: 1851484 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CTOR (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: September 30 - **Filer category**:
Emerging growth company - **Business address**: 11 COMMERCE DRIVE, CRANFORD, NJ, 07016 - **Phone**: (908) 967-6677 - **Shares outstanding**: 92,981,204 as of 2026-08-13 (10-Q filed 2026-08-14) - **Former names**: TenX Keane Acquisition ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390026104694/ea0307034-8k_citius.htm) filed 2026-09-29 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1851484/000121390026093757/ea0302414-def14a_citius.htm) filed 2026-08-26 - [10-Q](https://www.sec.gov/Archives/edgar/data/1851484/000121390026090184/ea0301678-10q_citius.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390026090182/ea0302226-8k_citius.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390026088068/ea0301456-8k_citius.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390026085434/ea0300371-8k_citius.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390026063530/ea0292903-8k_citius.htm) filed 2026-06-01 - [S-3](https://www.sec.gov/Archives/edgar/data/1851484/000121390026062864/ea0291447-s3_citius.htm) filed 2026-05-29 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001851484), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Citius Oncology, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CTOR, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Citius Oncology, Inc. - **Ticker**: CTOR - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US17331Y1091 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CTOR/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/citius-oncology/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Citius Oncology (CTOR) news: going concern and offering", 2026-10-31, https://aibio.space/companies/citius-oncology/